Relative Bioavailability With PF-05089771 Capsule Versus Oral Dispersion

• Experimental: Oral disperion fasted
  
  A single dose of 450 mg PF-05089771 TS oral dispersion in fasted conditions.
  Intervention: Drug: PF-05089771
• Experimental: Capsule fasted
  
  single dose of 450 mg PF-05089771 TS as 3 x 150 mg capsules in fasted conditions
  Intervention: Drug: PF-05089771
• Experimental: Capsule fed
  
  single dose of 450 mg PF-05089771 TS as 3 x 150 mg capsules in fed conditions
  Intervention: Drug: PF-05089771

Inclusion Criteria:

• Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests). Females must be of non-childbearing potential.
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
• An informed consent document signed and dated by the subject or a legally acceptable representative, indicating that the subject has been informed of all pertinent aspects of the trial.
• Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal (i.e recurrent uric nephrolithiasis), endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
• Any condition possibly affecting drug absorption (eg, gastrectomy)